NDLI: Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Please wait, while we are loading the content...

Mechanisms of Epileptogenesis in Pediatric Epileptic Syndromes: Rasmussen Encephalitis, Infantile Spasms, and Febrile Infection-related Epilepsy Syndrome (FIRES)

Autoimmune Epilepsies

Molecular Biomarkers of Epileptogenesis

Genetic Biomarkers in Epilepsy

Electrophysiological Biomarkers of Epilepsy

Neuroimaging the Epileptogenic Process

Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies

The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

Anti-epileptogenic Clinical Trial Designs in Epilepsy: Issues and Options

Effects of Marketed Antiepileptic Drugs and Placebo in the Human Photosensitivity Screening Protocol

Resveratrol Improves Motoneuron Function and Extends Survival in SOD1$^{G93A}$ ALS Mice

Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease

Molecular Tweezers Targeting Transthyretin Amyloidosis

NeuroRX : Volume 11, Issue 1, January 2014

Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Content Provider	Springer Nature Link
Author	Kanner, Andres M. Mazarati, Andrey Koepp, Matthias
Copyright Year	2014
Abstract	The last decade has witnessed a significant shift on our understanding of the relationship between psychiatric disorders and epilepsy. While traditionally psychiatric disorders were considered as a complication of the underlying seizure disorder, new epidemiologic data, supported by clinical and experimental research, have suggested the existence of a bidirectional relation between the two types of conditions: not only are patients with epilepsy at greater risk of experiencing a psychiatric disorder, but patients with primary psychiatric disorders are at greater risk of developing epilepsy. Do these data suggest that some of the pathogenic mechanisms operant in psychiatric comorbidities play a role in epileptogenesis? The aim of this article is to review the epidemiologic data that demonstrate that primary psychiatric disorders are more frequent in people who develop epilepsy, before the onset of the seizure disorder than among controls. The next question looks at the available data of pathogenic mechanisms of primary mood disorders and their potential for facilitating the development and/or exacerbation in the severity of epileptic seizures. Finally, we review data derived from experimental studies in animal models of depression and epilepsy that support a potential role of pathogenic mechanisms of mood disorders in the development of epileptic seizures and epileptogenesis. The data presented in this article do not yet establish conclusive evidence of a pathogenic role of psychiatric comorbidities in epileptogenesis, but raise important research questions that need to be investigated in experimental, clinical, and population-based epidemiologic research studies.
Starting Page	358
Ending Page	372
Page Count	15
File Format	PDF
ISSN	19337213
Journal	NeuroRX
Volume Number	11
Issue Number	2
e-ISSN	18787479
Language	English
Publisher	Springer US
Publisher Date	2014-04-10
Publisher Institution	American Society for Experimental NeuroTherapeutics
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Major depressive disorder Serotonin Opioids Selective serotonin-reuptake inhibitors Hypothalamic–pituitary–adrenal axis Glutamate GABA Neurosciences Neurology Neurosurgery Neurobiology
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical) Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder

Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.

Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction

Major Depressive Disorder and Hypothalamic-Pituitary-Adrenal Axis Activity

Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors

Inhibition-Based Biomarkers for Autism Spectrum Disorder

Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.

Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Similar Documents

Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder

Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.

Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction

Major Depressive Disorder and Hypothalamic-Pituitary-Adrenal Axis Activity

Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors

Inhibition-Based Biomarkers for Autism Spectrum Disorder

Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.

Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)